• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nutr Metab Cardiovasc Dis Cardiovascular Disease Potentially Contributes to the Progression and Poor Prognosis of COVID-19

tetano

Editor, Senior Moderator
Nutr Metab Cardiovasc Dis


. 2020 Apr 18;S0939-4753(20)30134-4.
doi: 10.1016/j.numecd.2020.04.013. Online ahead of print.
Cardiovascular Disease Potentially Contributes to the Progression and Poor Prognosis of COVID-19


Mingyue Li[SUP] 1 [/SUP], Yalan Dong[SUP] 1 [/SUP], Haijun Wang[SUP] 2 [/SUP], Weina Guo[SUP] 1 [/SUP], Haifeng Zhou[SUP] 1 [/SUP], Zili Zhang[SUP] 1 [/SUP], Chunxia Tian[SUP] 1 [/SUP], Keye Du[SUP] 2 [/SUP], Rui Zhu[SUP] 1 [/SUP], Li Wang[SUP] 3 [/SUP], Lei Zhao[SUP] 4 [/SUP], Heng Fan[SUP] 1 [/SUP], Shanshan Luo[SUP] 5 [/SUP], Desheng Hu[SUP] 6 [/SUP]



Affiliations

Abstract

Background and aim: A novel coronavirus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) caused pneumonia, Coronavirus Disease 2019 (COVID-19), broke out in Wuhan, China in December 2019, and spread all over the world. Patients with COVID-19 showed huge differences in the hospital stay, progression, and prognosis. As reported, the comorbidities may play an important role in COVID-19. Here, we aim to address the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19.
Methods and results: Eighty-three confirmed COVID-19 patients were divided into CVD (n = 42) and non-CVD (n = 41) group according to their medical history. Medical records including demographic data, medical history, clinical characteristics, laboratory examinations, chest computed tomography (CT), and treatment measures were collected, analyzed, and compared between the two groups. COVID-19 patients with CVD showed (1) more severe pathological changes in the lungs, (2) elevated injury-related enzymes including α-hydroxybutyrate dehydrogenase (HDBH), lactic dehydrogenase (LDH), γ-glutamyltransferase (GGT), creatine kinase (CK), and alanine aminotransferase (ALT), (3) significantly increased uncontrolled inflammation related markers, such as c-reactive protein (CRP), interleukin (IL)-6, serum ferritin, erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA), (4) serious hypercoagulable status reflected by increased D-dimer and serum fibrinogen (FIB), and (5) higher mortality, compared to COVID-19 patients without CVD.
Conclusions: Our data indicated that CVD is a strong risk factor for rapid progression and bad prognosis of COVID-19. More intensive medical care should be applied to patients with CVD to prevent rapid deterioration of the disease.

Keywords: COVID-19; Cardiovascular disease; Prognosis.
 
Back
Top Bottom